SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001479290-17-000036
Filing Date
2017-08-04
Accepted
2017-08-04 17:08:06
Documents
62
Period of Report
2017-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q rvncq21710q.htm 10-Q 1105759
2 EXHIBIT 31.1 rvnc-q217exhibit311.htm EX-31.1 13581
3 EXHIBIT 31.2 rvnc-q217exhibit312.htm EX-31.2 13478
4 EXHIBIT 32.1 rvnc-q217exhibit321.htm EX-32.1 6241
5 EXHIBIT 32.2 rvnc-q217exhibit322.htm EX-32.2 6266
  Complete submission text file 0001479290-17-000036.txt   4727070

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT rvnc-20170630.xml EX-101.INS 913974
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rvnc-20170630.xsd EX-101.SCH 39076
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT rvnc-20170630_cal.xml EX-101.CAL 61259
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT rvnc-20170630_def.xml EX-101.DEF 158741
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rvnc-20170630_lab.xml EX-101.LAB 460435
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rvnc-20170630_pre.xml EX-101.PRE 271336
Mailing Address 7555 GATEWAY BLVD. NEWARK CA 94560
Business Address 7555 GATEWAY BLVD. NEWARK CA 94560 510-742-3400
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36297 | Film No.: 171009415
SIC: 2834 Pharmaceutical Preparations